Regulatory T-Cells in Treatment of Type-1 Diabetes: Types and Approaches
DOI:
https://doi.org/10.17140/DROJ-1-109Keywords:
Type-1 Diabetes, Regulatory T-cells, Autoimmune diabetes, Immune suppression, Antigen specificAbstract
Regulatory T-cells (Tregs) play important role in regulation of immune responses to self-antigens. Alterations in frequency and function of Tregs have been reported in Type 1 Diabetes (T1D) subjects. Tregs have the potential to prevent destruction of pancreatic
beta cells by targeting effector T-cells (Teff) and other immune cells causing inflammation. Therefore, strategies to increase Treg cell numbers and function are being explored as potential immunotherapeutic approaches in treating T1D. Today, several groups are involved in exploring different Treg cell types, sources, induction procedures and experimental systems in pursuit of generation of highly efficacious and stable Tregs for their clinical applications. Various protocols have been developed for the induction and expansion of islet antigen specific Tregs and polyclonal Tregs. Studies have shown that antigen specific Tregs are required at less number and are more efficient than polyclonal Tregs in suppressing autoimmune diabetes and they do not cause generalized immune suppression. Alternatively, generation of colonic Tregs (cTregs) has also gathered attention in recent years as an approach to limit pancreatic inflammation via gut induced tolerance. With a definitive treatment for T1D still elusive, application of Tregs as
a part of combination therapy seems promising in treatment of T1D.
References
Knight RR, Kronenberg D, Zhao M, et al. Human β-cell killing by autoreactive preproinsulin-specific CD8 T-cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity. Diabetes. 2013; 62(1): 205-213. doi: 10.2337/db12-0315
Luce S, Lemonnier F, Briand J-P, et al. Single insulin-specific CD8+ T-cells show characteristic gene expression profiles in human type 1 diabetes. Diabetes. 2011; 60(12): 3289-3299. doi: 10.2337/db11-0270
Skowera A, Ladell K, McLaren JE, et al. β-cell-specific CD8 T-cell phenotype in type 1 diabetes reflects chronic autoantigen exposure. Diabetes. 2014; DB-140332.
Sachdeva N, Paul M, Badal D, et al. Preproinsulin specific CD8+ T-cells in subjects with latent autoimmune diabetes show lower frequency and different pathophysiological characteristics than those with type 1 diabetes. Clinical Immunology. 2015. doi: 10.1016/j.clim.2015.01.005
Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T-cells in immunological tolerance to self and non-self. Nature immunology. 2005; 6(4): 345-352. doi: 10.1038/ni1178
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Pillars article: immunologic self-tolerance maintained by activated T-cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995.
Maloy KJ, Powrie F. Regulatory T-cells in the control of immune pathology. Nature immunology. 2001; 2(9): 816-822. doi: 10.1038/ni0901-816
Shevach EM. CD4+ CD25+ suppressor T-cells: more questions than answers. Nature Reviews Immunology. 2002; 2(6): 389-400. doi: 10.1038/nri821
Ramsdell F. Foxp3 and natural regulatory T-cells: key to a cell lineage? Immunity. 2003; 19(2): 165-168.
Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression in-versely correlates with FoxP3 and suppressive function of hu-man CD4+ T reg cells. The Journal of experimental medicine. 2006; 203(7): 1701-1711. doi: 10.1084/jem.20060772
Badami E, Sorini C, Coccia M, et al. Defective differentiation of regulatory FoxP3+ T-cells by small-intestinal dendritic cells in patients with type 1 diabetes. Diabetes. 2011; 60(8): 2120- 2124. doi: 10.2337/db10-1201
Ferraro A, Socci C, Stabilini A, et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes. 2011; 60(11): 2903-2913. doi: 10.2337/db11-0090
Taams LS, Boot EP, van Eden W, Wauben MH. Anergic T-cells modulate the T-cell activating capacity of antigen-presenting cells. Journal of autoimmunity. 2000; 14(4): 335-341.
Eddahri F, Oldenhove G, Denanglaire S, Urbain J, Leo O, Andris F. CD4+ CD25+ regulatory T-cells control the magnitude of T-dependent humoral immune responses to exogenous antigens. European journal of immunology. 2006; 36(4): 855- 863. doi: 10.1002/eji.200535500
Mempel TR, Pittet MJ, Khazaie K, et al. Regulatory T-cells reversibly suppress cytotoxic T-cell function independent of effector differentiation. Immunity. 2006; 25(1): 129-141.
Bluestone JA, Tang Q. How do CD4+ CD25+ regulatory T-cells control autoimmunity? Current opinion in immunology. 2005; 17(6): 638-642.
Tang Q, Bluestone JA. The Foxp3+ regulatory T-cell: a jack of all trades, master of regulation. Nature immunology. 2008; 9(3): 239-244. doi: 10.1038/ni1572
Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunological reviews. 2001; 182(1): 68-79. doi: 10.1034/j.1600-065X.2001.1820105.x
Pot C, Apetoh L, Kuchroo VK, editors. Type 1 regulatory T-cells (Tr1) in autoimmunity. Seminars in immunology. Elsevier, 2011. doi: 10.1016/j.smim.2011.07.005
Okamura T, Fujio K, Sumitomo S, Yamamoto K. Roles of LAG3 and EGR2 in regulatory T-cells. Annals of the rheumatic diseases. 2012; 71(Suppl 2): i96-i100. doi: 10.1136/ annrheumdis-2011-200588
Yadav M, Louvet C, Davini D, et al. Neuropilin-1 distinguishes natural and inducible regulatory T-cells among regulatory T-cell subsets in vivo. The Journal of experimental medicine. 2012; 209(10): 1713-1722. doi: 10.1084/jem.20120822
de Lafaille MAC, Lafaille JJ. Natural and adaptive foxp3+ regulatory T-cells: more of the same or a division of labor? Immunity. 2009; 30(5): 626-635. doi: 10.1016/j. immuni.2009.05.002
Lu L, Ma J, Li Z, et al. All-trans retinoic acid promotes TGF-β-induced Tregs via histone modification but not DNA demethy-lation on Foxp3 gene locus. PloS one. 2011; 6(9): e24590. doi: 10.1371/journal.pone.0024590
Tai X, Cowan M, Feigenbaum L, Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T-cell differentiation independently of interleukin 2. Nature immunology. 2005; 6(2): 152-162. doi: 10.1038/ni1160
Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differ-entiation, and gut homing in the face of high levels of co-stim-ulation. The Journal of experimental medicine. 2007; 204(8): 1765-1774. doi: 10.1084/jem.20070719
Shevach EM, Tran DQ, Davidson TS, Andersson J. The critical contribution of TGF-β to the induction of Foxp3 expression and regulatory T-cell function. European journal of immunology. 2008; 38(4): 915-917. doi: 10.1002/eji.200738111
Bilate AM, Lafaille JJ. Induced CD4+ Foxp3+ regulatory T-cells in immune tolerance. Annual review of immunology. 2012; 30: 733-758. doi: 10.1146/annurev-immunol-020711-075043
Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T-cells that control autoimmune diabetes. Immunity. 2000; 12(4): 431-440.
Cheng G, Yu A, Dee MJ, Malek TR. IL-2R signaling is essential for functional maturation of regulatory T-cells during thymic development. The Journal of Immunology. 2013; 190(4): 1567-1575. doi: 10.4049/jimmunol.1201218
Stritesky GL, Jameson SC, Hogquist KA. Selection of self-reactive T-cells in the thymus. Annual review of immunology. 2012; 30: 95.
Hsieh C-S, Lee H-M, Lio C-WJ. Selection of regulatory T-cells in the thymus. Nature Reviews Immunology. 2012; 12(3): 157-167. doi: 10.1038/nri3155
Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T-cells: mechanisms of differentiation and function. Annual review of immunology. 2012; 30: 531-564. doi: 10.1146/annurev. immunol.25.022106.141623
Lee H-M, Bautista JL, Scott-Browne J, Mohan JF, Hsieh C-S. A broad range of self-reactivity drives thymic regulatory T-cell selection to limit responses to self. Immunity. 2012; 37(3): 475-486. doi: 10.1016/j.immuni.2012.07.009
Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proceedings of the National Academy of Sciences. 2010; 107(27): 12204-12209. doi: 10.1073/pnas.0909122107
Lathrop SK, Bloom SM, Rao SM, et al. Peripheral education of the immune system by colonic commensal microbiota. Na-ture. 2011; 478(7368): 250-254. doi: 10.1038/nature10434
Lin X, Chen M, Liu Y, et al. Advances in distinguishing natural from induced Foxp3+ regulatory T-cells. International journal of clinical and experimental pathology. 2013; 6(2): 116.
Bruder D, Probst-Kepper M, Westendorf AM, et al. Frontline: Neuropilin-1: a surface marker of regulatory T-cells. European journal of immunology. 2004; 34(3): 623-630. doi: 10.1002/ eji.200324799
Thornton AM, Korty PE, Tran DQ, et al. Expression of He-lios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. The Journal of Immunology. 2010; 184(7): 3433-3441. doi: 10.4049/jimmunol.0904028
Kim YC, Bhairavabhotla R, Yoon J, et al. Oligodeoxynucle-otides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion. Blood. 2012; 119(12): 2810- 2818. doi: 10.1182/blood-2011-09-377895
Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood. 2009; 114(18): 3727-3735. doi: 10.1182/blood-2009-05-219584
McClymont SA, Putnam AL, Lee MR, et al. Plasticity of human regulatory T-cells in healthy subjects and patients with type 1 diabetes. The Journal of Immunology. 2011; 186(7): 3918-3926. doi: 10.4049/jimmunol.1003099
Kukreja A, Cost G, Marker J, et al. Multiple immuno-regula-tory defects in type-1 diabetes. The Journal of clinical investiga-tion. 2002; 109(109 (1)): 131-140. doi: 10.1172/JCI13605
Ryba M, Rybarczyk-Kapturska K, Zorena K, Myśliwiec M, Myśliwska J. Lower Frequency of CD62L high and Higher Fre-quency of TNFR2. Mediators of inflammation. 2011; 2011. doi: 10.1155/2011/645643
Ryba-Stanisławowska M, Skrzypkowska M, Myśliwska J, Myśliwiec M. The serum IL-6 profile and Treg/Th17 peripheral cell populations in patients with type 1 diabetes. Mediators of inflammation. 2013; 2013. doi: 10.1155/2013/205284
Ryba-Stanisławowska M, Rybarczyk-Kapturska K, Myśliwiec M, Myśliwska J. Elevated Levels of Serum IL-12 and IL-18 are Associated with Lower Frequencies of CD4+ CD25highFOXP3+ Regulatory T-cells in Young Patients with Type 1 Diabetes. Inflammation. 2014; 37(5): 1513-1520. doi: 10.1007/s10753-014-9878-1
Brusko T, Wasserfall C, McGrail K, et al. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes. 2007; 56(3): 604-612. doi: 10.2337/db06-1248
Xufré C, Costa M, Roura-Mir C, et al. Low frequency of GITR+ T-cells in ex vivo and in vitro expanded Treg cells from type 1 diabetic patients. International immunology. 2013: dxt020.
Zóka A, Barna G, Somogyi A, et al. Extension of the CD4+ Foxp3+ CD25-/low regulatory T-cell subpopulation in type 1 diabetes mellitus. Autoimmunity. 2014; 1-9. doi: 10.3109/08916934.2014.992518
Willcox A, Richardson S, Bone A, Foulis A, Morgan N. Analysis of islet inflammation in human type 1 diabetes. Clini-cal & Experimental Immunology. 2009; 155(2): 173-181. doi: 10.1111/j.1365-2249.2008.03860.x
Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4+ CD25+ T-cells from patients with type 1 diabetes. Diabetes. 2005; 54(1): 92-99. doi: 10.2337/diabetes.54.1.92
Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes. 2005; 54(5): 1407-1414. doi: 10.2337/diabetes.54.5.1407
Haseda F, Imagawa A, Murase-Mishiba Y, Terasaki J, Hanafusa T. CD4+ CD45RA− FoxP3high activated regulatory T-cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. Clinical & Experimental Immunology. 2013; 173(2): 207-216. doi: 10.1111/ cei.12116
Long SA, Cerosaletti K, Bollyky PL, et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+ CD25+ regulatory T-cells of type 1 diabetic subjects. Diabetes. 2010; 59(2): 407-415. doi: 10.2337/db09- 0694
Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T-cells in vivo. Nature immunology. 2009; 10(9): 1000-1007. doi: 10.1038/ni.1774
Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner JH. The effector T-cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T-cells. The Journal of Immunology. 2008; 181(10): 7350-7355. doi: 10.4049/jimmunol.181.10.7350
Lawson J, Tremble J, Dayan C, et al. Increased resistance to CD4+ CD25hi regulatory T-cell-mediated suppression in patients with type 1 diabetes. Clinical & Experimental Immunology. 2008; 154(3): 353-359. doi: 10.1111/j.1365-2249.2008.03810.x
Zhang J, Gao W, Yang X, et al. Tolerogenic vaccination reduced effector memory CD4 T-cells and induced effector memory Treg cells for type I diabetes treatment. PloS one. 2013; 8(7): e70056. doi: 10.1371/journal.pone.0070056
Johnson MC, Garland AL, Nicolson SC, et al. β-Cell–Specific IL-2 Therapy Increases Islet Foxp3+ Treg and Suppresses Type 1 Diabetes in NOD Mice. Diabetes. 2013; 62(11): 3775-3784. doi: 10.2337/db13-0669
Bilbao D, Luciani L, Johannesson B, Piszczek A, Rosenthal N. Insulin-like growth factor-1 stimulates regulatory T-cells and suppresses autoimmune disease. EMBO molecular medicine. 2014; e201303376.
Tian J, Dang H, Nguyen AV, Chen Z, Kaufman DL. Com-bined therapy with GABA and proinsulin/alum acts synergisti-cally to restore long-term normoglycemia by modulating T-Cell autoimmunity and promoting β-Cell replication in newly diabet-ic NOD mice. Diabetes. 2014; 63(9): 3128-3134. doi: 10.2337/ db13-1385
Turner MS, Isse K, Fischer DK, Turnquist HR, Morel PA. Low TCR signal strength induces combined expansion of Th2 and regulatory T-cell populations that protect mice from the development of type 1 diabetes. Diabetologia. 2014; 57(7): 1428-1436. doi: 10.1007/s00125-014-3233-9
Lin G-J, Sytwu H-K, Yu J-C, et al. Dimethyl sulfoxide inhibits spontaneous diabetes and autoimmune recurrence in non-obese diabetic mice by inducing differentiation of regulatory T-cells. Toxicology and applied pharmacology. 2015; 282(2): 207-214. doi: 10.1016/j.taap.2014.11.012
Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, et al. Therapy of type 1 diabetes with CD4+ CD25 high CD127- regulatory T-cells prolongs survival of pancreatic islets-Results of one year follow-up. Clinical Immunology. 2014; 153(1): 23- 30. doi: 10.1016/j.clim.2014.03.016
Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nature Reviews Immunology. 2005; 5(4): 343-349. doi: 10.1038/nri1574
Hill JA, Hall JA, Sun C-M, et al. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4+ CD44 hi cells. Immunity. 2008; 29(5): 758-770. doi: 10.1016/j. immuni.2008.09.018
Rossetti M, Spreafico R, Saidin S, et al. Ex vivo-expanded but not in vitro-induced human regulatory T-cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T-cell-specific demethylated region. The Journal of Immunology. 2015; 194(1): 113-124. doi: 10.4049/jimmunol.1401145
Fantini M, Becker C, Monteleone G, Pallone F, Galle P, Neurath M. TGF-beta induces a regulatory phenotype in CD4+ CD25-T-cells through FoxP3 induction and dowuregulation of Smad7. Gastroenterology. Wb Saunders Co Independence Square West Curtis Center, Ste 300, Philadelphia, PA 19106- 3399 USA, 2004 .
Josefowicz SZ, Rudensky A. Control of regulatory T-cell lineage commitment and maintenance. Immunity. 2009; 30(5): 616-625. doi: 10.1016/j.immuni.2009.04.009
Lu Y, Gu J, Lu H, et al. iTreg induced from CD39+ naive T-cells demonstrate enhanced proliferate and suppressive ability. International immunopharmacology. 2015. doi: 10.1016/j. intimp.2015.03.039
Chai J-G, Coe D, Chen D, Simpson E, Dyson J, Scott D. In vitro expansion improves in vivo regulation by CD4+ CD25+ regulatory T-cells. The Journal of Immunology. 2008; 180(2): 858-869. doi: 10.4049/jimmunol.180.2.858
Groux H, O’Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997; 389(6652): 737-742.
Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10–producing, nonproliferating CD4+ T-cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. The Journal of experimental medicine. 2000; 192(9): 1213-1222.
Gad M, Kristensen NN, Kury E, Claesson MH. Characteriza-tion of T-regulatory cells, induced by immature dendritic cells, which inhibit enteroantigen-reactive colitis-inducing T-cell re-sponses in vitro and in vivo. Immunology. 2004; 113(4): 499- 508. doi: 10.1111/j.1365-2567.2004.01977.x
Rao PE, Petrone AL, Ponath PD. Differentiation and expansion of T-cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-β. The Journal of Immunology. 2005; 174(3): 1446-1455. doi: 10.4049/jimmunol.174.3.1446
Walker MR, Carson BD, Nepom GT, Ziegler SF, Buckner JH. De novo generation of antigen-specific CD4+ CD25+ regulatory T-cells from human CD4+ CD25–cells. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(11): 4103-4108.
DiPaolo RJ, Brinster C, Davidson TS, Andersson J, Glass D, Shevach EM. Autoantigen-specific TGFβ-induced Foxp3+ regulatory T-cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T-cells. The Journal of Immunology. 2007; 179(7): 4685-4693. doi: 10.4049/ jimmunol.179.7.4685
Zhao C, Shi G, Vistica BP, et al. Induced regulatory T-cells (iTregs) generated by activation with anti-CD3/CD28 antibodies differ from those generated by the physiological-like activation with antigen/APC. Cellular immunology. 2014; 290(2): 179- 184. doi: 10.1016/j.cellimm.2014.06.004
Kang H-K, Liu M, Datta SK. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T-cells and contraction of inflammatory Th17 cells. The Journal of Immunology. 2007; 178(12): 7849-7858. doi: 10.4049/ jimmunol.178.12.7849
Hamdi H, Godot V, Maillot M-C, et al. Induction of antigen-specific regulatory T lymphocytes by human dendritic cells ex-pressing the glucocorticoid-induced leucine zipper. Blood. 2007; 110(1): 211-219.
Tarbell KV, Petit L, Zuo X, et al. Dendritic cell–expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T-cells restore normoglycemia in diabetic NOD mice. The Journal of experimental medicine. 2007; 204(1): 191-201. doi: 10.1084/ jem.20061631
Pillai V, Ortega SB, Wang C, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clinical immunology. 2007; 123(1): 18-29. doi: 10.1016/j. clim.2006.10.014
Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A. Generation of CD4+ or CD8+ regulatory T-cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica. 2007; 92(7): 881-888. doi: 10.3324/haematol.11240
Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T-cells. The Journal of experimental medicine. 2009; 206(13): 3015-3029. doi: 10.1084/jem.20090847
Long SA, Walker MR, Rieck M, et al. Functional islet-specific Treg can be generated from CD4+ CD25- T-cells of healthy and type 1 diabetic subjects. European journal of immunology. 2009; 39(2): 612-620. doi: 10.1002/eji.200838819
Brusko TM, Koya RC, Zhu S, et al. Human antigen-specific regulatory T-cells generated by T-cell receptor gene transfer. PloS one. 2010; 5(7): e11726. doi: 10.1371/journal.pone.0011726
Zheng J, Liu Y, Lau Y-L, Tu W. CD40-activated B cells are more potent than immature dendritic cells to induce and expand CD4+ regulatory T-cells. Cellular & molecular immunology. 2010; 7(1): 44-50.
Mota C, Nunes-Silva V, Pires AR, et al. Delta-like 1-mediated notch signaling enhances the in vitro conversion of human memory CD4 T-cells into FOXP3-expressing regulatory T-cells. The Journal of Immunology. 2014; 193(12): 5854-5862. doi: 10.4049/jimmunol.1400198
Romani R, Pirisinu I, Calvitti M, et al. Stem cells from hu-man amniotic fluid exert immunoregulatory function via se-creted indoleamine 2, 3-dioxygenase1. Journal of cellular and molecular medicine. 2015. doi: 10.1111/jcmm.12534
Akbarpour M, Goudy KS, Cantore A, et al. Insulin B chain 9-23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs. Science Translational Medicine. 2015; 7(289): 289ra81-289ra81. doi: 10.1126/sci-translmed.aaa3032
Chatenoud L, Bluestone JA. CD3-specific antibodies: a por-tal to the treatment of autoimmunity. Nature Reviews Immunol-ogy. 2007; 7(8): 622-632. doi: 10.1038/nri2134
Orban T, Farkas K, Jalahej H, et al. Autoantigen-specific regulatory T-cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. Journal of autoimmunity. 2010; 34(4): 408-415. doi: 10.1016/j.jaut.2009.10.005
Bock G, Prietl B, Mader JK, et al. The effect of vitamin D supplementation on peripheral regulatory T-cells and β cell function in healthy humans: a randomized controlled trial. Diabetes/metabolism research and reviews. 2011; 27(8): 942- 945. doi: 10.1002/dmrr.1276
Hjorth M, Axelsson S, Rydén A, Faresjö M, Ludvigsson J, Casas R. GAD-alum treatment induces GAD 65-specific CD4+ CD25 high FOXP3+ cells in type 1 diabetic patients. Clinical immunology. 2011; 138(1): 117-126.
Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, et al. Administration of CD4+ CD25 high CD127-regulatory T-cells preserves β-Cell function in Type 1 Diabetes in children. Diabetes care. 2012; 35(9): 1817-1820. doi: 10.2337/dc12-0038
Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 combi-nation therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes. 2012; 61(9): 2340-2348. doi: 10.2337/db12-0049
Haller MJ, Gitelman SE, Gottlieb PA, et al. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. The Journal of clinical investi-gation. 2014; 125(125(1)).
Bonifacio E, Ziegler A-G, Klingensmith G, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA. 2015; 313(15): 1541-1549. doi: 10.1001/ jama.2015.2928
Penaranda C, Bluestone JA. Is antigen specificity of autoreactive T-cells the key to islet entry? Immunity. 2009; 31(4): 534-536. doi: 10.1016/j.immuni.2009.09.006
Lennon GP, Bettini M, Burton AR, et al. T-cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity. 2009; 31(4): 643-653. doi: 10.1016/j.immuni.2009.07.008
Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T-cells suppress autoimmune diabetes. The Journal of experimental medicine. 2004; 199(11): 1455-1465. doi: 10.1084/jem.20040139
Bluestone JA, Tang Q. Therapeutic vaccination using CD4+ CD25+ antigen-specific regulatory T-cells. Proceedings of the National Academy of Sciences. 2004; 101(Suppl 2): 14622- 14626. doi: 10.1073/pnas.0405234101
Larkin J, Picca CC, Caton AJ. Activation of CD4+ CD25+ regulatory T-cell suppressor function by analogs of the selecting peptide. European journal of immunology. 2007; 37(1): 139- 146. doi: 10.1002/eji.200636577
Kasagi S, Zhang P, Che L, et al. In vivo–generated antigen-specific regulatory T-cells treat autoimmunity without compromising antibacterial immune response. Science translational medicine. 2014; 6(241): 241ra78-241ra78. doi: 10.1126/scitranslmed.3008895
Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T-cells via a TGF-β–and retinoic acid–dependent mechanism. The Journal of experimental medicine. 2007; 204(8): 1757-1764. doi: 10.1084/jem.20070590
Ito T, Yang M, Wang Y-H, et al. Plasmacytoid dendritic cells prime IL-10–producing T regulatory cells by inducible co-stimulator ligand. The Journal of experimental medicine. 2007; 204(1): 105-115. doi: 10.1084/jem.20061660
Yamazaki S, Dudziak D, Heidkamp GF, et al. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T-cells. The Journal of Immunology. 2008; 181(10): 6923-6933. doi: 10.4049/jimmunol.181.10.6923
Tu W, Lau Y-L, Zheng J, et al. Efficient generation of human alloantigen-specific CD4+ regulatory T-cells from naive precursors by CD40-activated B cells. Blood. 2008; 112(6): 2554-2562. doi: 10.1182/blood-2008-04-152041
Noyan F, Lee YS, Zimmermann K, et al. Isolation of human antigen-specific regulatory T-cells with high suppressive function. European journal of immunology. 2014; 44(9): 2592- 2602. doi: 10.1002/eji.201344381
Yang XO, Nurieva R, Martinez GJ, et al. Molecular antagonism and plasticity of regulatory and inflammatory T-cell programs. Immunity. 2008; 29(1): 44-56. doi: 10.1016/j. immuni.2008.05.007
Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural Foxp3+ T-cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proceedings of the National Academy of Sciences. 2009; 106(6): 1903-1908. doi: 10.1073/ pnas.0811556106
Oldenhove G, Bouladoux N, Wohlfert EA, et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phe-notype during lethal infection. Immunity. 2009; 31(5): 772-786. doi: 10.1016/j.immuni.2009.10.001
Miyao T, Floess S, Setoguchi R, et al. Plasticity of Foxp3+ T-cells reflects promiscuous Foxp3 expression in conventional T-cells but not reprogramming of regulatory T-cells. Immunity. 2012; 36(2): 262-275. doi: 10.1016/j.immuni.2011.12.012
Yurchenko E, Shio MT, Huang TC, et al. Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T-cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PloS one. 2012; 7(4): e35572. doi: 10.1371/ journal.pone.0035572
Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+ CD25+ T-cell-mediated suppression by dendritic cells. Science. 2003; 299(5609): 1033-1036. doi: 10.1126/ science.1078231
Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+ CD25hi T-regulatory cells. Blood. 2006; 108(1): 253-261. doi: 10.1182/blood-2005-11-4567
Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T-cell-mediated suppression of human CD4+ T lymphocytes. The Journal of Immunology. 2007; 178(2): 732- 739. doi: 10.4049/jimmunol.178.2.732
Ruprecht CR, Gattorno M, Ferlito F, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T-cells in inflamed synovia. The Journal of experimental medicine. 2005; 201(11): 1793-1803. doi: 10.1084/jem.20050085
Komatsu N, Okamoto K, Sawa S, et al. Pathogenic conversion of Foxp3+ T-cells into TH17 cells in autoimmune arthritis. Nature medicine. 2014; 20(1): 62-68. doi: 10.1038/ nm.3432
Vaarala O, Atkinson MA, Neu J. The Perfect storm for type 1 diabetes the complex interplay between intestinal micro-biota, gut permeability, and mucosal immunity. Diabetes. 2008; 57(10): 2555-2562. doi: 10.2337/db08-0331
Kukreja A, Maclaren NK. NKT-cells and type-1 diabetes and the” hygiene hypothesis” to explain the rising incidence rates. Diabetes technology & therapeutics. 2002; 4(3): 323-333. doi: 10.1089/152091502760098465
Sun C-M, Hall JA, Blank RB, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. The Journal of experimental medi-cine. 2007; 204(8): 1775-1785. doi: 10.1084/jem.20070602
Coombes JL, Powrie F. Dendritic cells in intestinal immune regulation. Nature Reviews Immunology. 2008; 8(6): 435-446. doi: 10.1038/nri2335
Jaakkola I, Jalkanen S, Hänninen A. Diabetogenic T-cells are primed both in pancreatic and gut-associated lymph nodes in NOD mice. European journal of immunology. 2003; 33(12): 3255-3264. doi: 10.1002/eji.200324405
Hänninen A, Nurmela R, Maksimow M, Heino J, Jalkanen S, Kurts C. Islet β-cell-specific T-cells can use different homing mechanisms to infiltrate and destroy pancreatic islets. The American journal of pathology. 2007; 170(1): 240-250. doi: 10.2353/ajpath.2007.060142
Geuking MB, Cahenzli J, Lawson MA, et al. Intestinal bacterial colonization induces mutualistic regulatory T-cell responses. Immunity. 2011; 34(5): 794-806. doi: 10.1016/j. immuni.2011.03.021
Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013; 500(7461): 232-236. doi: 10.1038/ nature12331
Zuo L, Yuan K-T, Yu L, Meng Q-H, Chung PC-K, Yang D-H. Bifidobacterium infantis attenuates colitis by regulating T-cell subset responses. World journal of gastroenterology: WJG. 2014; 20(48): 18316. doi: 10.3748/wjg.v20.i48.18316
Calcinaro F, Dionisi S, Marinaro M, et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia. 2005; 48(8): 1565-1575. doi: 10.1007/ s00125-005-1831-2
Robert S, Gysemans C, Takiishi T, et al. Oral delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by Lactococ-cus lactis reverses diabetes in recent-onset NOD mice. Diabetes. 2014; 63(8): 2876-287. doi: 10.2337/db13-1236
Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013; 341(6145): 569-573. doi: 10.1126/ science.1241165
Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T-cells. Nature. 2013; 504(7480): 446-450. doi: 10.1038/ nature12721
Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. The Journal of neuroscience. 2003; 23(28): 9418-9427.
Tao R, de Zoeten EF, Özkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T-cells. Nature medicine. 2007; 13(11): 1299-1307. doi: 10.1038/nm1652
De Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 2010; 138(2): 583-594. doi: 10.1053/j.gastro.2009.10.037
Manicassamy S, Reizis B, Ravindran R, et al. Activation of β-catenin in dendritic cells regulates immunity versus toler-ance in the intestine. Science. 2010; 329(5993): 849-853. doi: 10.1126/science.1188510
Ganapathy V, Thangaraju M, Prasad PD, Martin PM, Singh N. Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the host. Current opinion in pharmacology. 2013; 13(6): 869-874. doi: 10.1016/j. coph.2013.08.006
Blad CC, Tang C, Offermanns S. G protein-coupled recep-tors for energy metabolites as new therapeutic targets. Nature Reviews Drug Discovery. 2012; 11(8): 603-619. doi: 10.1038/ nrd3777
Singh N, Gurav A, Sivaprakasam S, et al. Activation of Gpr109a, receptor for niacin and the commensal metabo-lite butyrate, suppresses colonic inflammation and carcino-genesis. Immunity. 2014; 40(1): 128-139. doi: 10.1016/j. immuni.2013.12.007
Kang SW, Kim SH, Lee N, et al. 1, 25-Dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region. The Jour-nal of Immunology. 2012; 188(11): 5276-5282. doi: 10.4049/ jimmunol.1101211
Takiishi T, Ding L, Baeke F, et al. Dietary supplementation with high doses of regular vitamin D3 safely reduces diabetes in-cidence in nod mice when given early and long-term. Diabetes. 2014; DB-131559. doi: 10.2337/db13-1559
Kunisawa J, Hashimoto E, Ishikawa I, Kiyono H. A pivotal role of vitamin B9 in the maintenance of regulatory T-cells in vitro and in vivo. PloS one. 2012; 7(2): e32094. doi: 10.1371/ journal.pone.0032094
Kim SV, Xiang WV, Kwak C, et al. GPR15-mediated hom-ing controls immune homeostasis in the large intestine mu-cosa. Science. 2013; 340(6139): 1456-1459. doi: 10.1126/sci-ence.1237013
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Diabetes Research (DR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
